x

Posted 30 May, 2023

NEVRO CORP appointed new CEO

CEO Change detected for ticker NYSE:NVRO in a 8-K filed on 30 May, 2023.


  As previously announced in the Current Report on Form 8-K filed on April 19, 2023 by Nevro Corp. (the "Company"), Kevin Thornal, the current Chief Executive Officer and President of the Company, was appointed to the Company's board of directors (the "Board") on May 25, 2023, immediately following the conclusion of the Company's 2023 Annual Meeting of Stockholders (the "Annual Meeting").  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of NEVRO CORP
Health Care/Life Sciences • Medical Equipment/Supplies
Nevro Corp. engages in the development of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes the senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.
Market Cap
$528M
View Company Details
NEVRO CORP by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously announced in the Current Report on Form 8-K filed on April 19, 2023 by Nevro Corp. (the "Company"), Kevin Thornal, the current Chief Executive Officer and President of the Company, was appointed to the Company's board of directors (the "Board") on May 25, 2023, immediately following the conclusion of the Company's 2023 Annual Meeting of Stockholders (the "Annual Meeting").